Analyst Sentiment Remains Bullish on CytomX Therapeutics (CTMX) Amid CX-2051 Therapy Progress

Core Insights - CytomX Therapeutics, Inc. (NASDAQ:CTMX) is identified as one of the 12 best multibagger stocks to consider for investment leading into 2026 [1] - Analyst sentiment remains predominantly positive, with 90% of analysts expressing bullish views and a median price target of $6.50, indicating a potential upside of 58.20% [2] Group 1: Analyst Ratings and Price Targets - H.C. Wainwright has reiterated a "Buy" rating for CytomX with a price target of $10.00, anticipating critical data for the CX-2051 therapy in colorectal cancer [3] - The analysis categorizes potential outcomes for CX-2051 into three scenarios: "slam dunk," "bull," and "bear," with specific benchmarks for each [4] Group 2: CX-2051 Therapy Progress - Under the "slam dunk" scenario, an objective response rate (ORR) of 25%-30% or higher is expected, with median progression-free survival (PFS) of at least six months [4] - The company is progressing towards enrolling approximately 100 patients for the CX-2051 program ahead of a planned Phase 1 update in Q1 2026 [5] - CX-2051 is positioned as a first-in-class EpCAM-directed antibody-drug conjugate (ADC) targeting late-line colorectal cancer and broader EpCAM-expressing tumors [5] Group 3: Company Overview - CytomX Therapeutics is a clinical-stage oncology company focused on developing conditionally activated biologics localized to tumors, including ADCs and T-cell engagers, aiming for safer and more effective cancer therapies [6]